TVM Healthcare MENA II

Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.

Recurv Pharma's RP-001 is a novel chemical entity (NCE) that is administered in a nano-emulsion formulation, concentrating medication delivery to the tumour while preserving healthy organs. Strong efficacy in a variety of pre-clinical tumour models, including non-small cell lung, breast, ovarian, prostate, pancreatic, and colorectal cancers, has allowed the chemical to show that it can destroy tumours even in multi-drug resistant tumours.

Developer of a gut microbiome therapy designed to advance microbiome research to address unmet and critical needs in healthcare. The company collects gut microbiome stools that will be used to advance microbiome research and treatment which will potentially save the lives of patients suffering from infections and other diseases and has also developed a test aiming to identify the types of gut microbiota, enabling medical professionals to advance human health through microbe science.

Egg Medical is a medical device company that offers EGGNEST, a passive protection designed to drastically reduce scatter radiation exposure for the entire cath lab team without disruption to workflow. It is an in integrated work platform built on a carbon fiber sled base designed to drastically reduce scatter radiation exposure without disrupting workflow.

Centogene AG is a leading genetic biotechnology company based in Rostock, Germany, specializing in genetic and biochemical diagnostic testing for rare hereditary disorders. The company offers a range of services to support the medical community, including genetic counseling, newborn screening, and biomarker analysis for lysosomal storage disorders. Centogene has developed a comprehensive rare disease platform that integrates epidemiologic, phenotypic, and genetic data, along with a biobank of blood samples, to aid in patient diagnosis and treatment. Additionally, the company collaborates with pharmaceutical partners to provide services such as patient recruitment, epidemiological insights, and biomarker discovery. Its diagnostic services are accessible through healthcare providers, facilitating targeted genetic sequencing for patients with various genetic disorders. With operations in multiple countries, including the United States and the United Arab Emirates, Centogene aims to improve awareness and treatment options for patients with rare diseases globally.

Access Vascular, Inc. is a medical technology company based in Bedford, Massachusetts, founded in 2015. The company specializes in developing venous access devices utilizing innovative hydrogel materials to significantly reduce the accumulation of blood components that can lead to thrombosis, infections, and other complications associated with intravenous therapy. Their product line includes peripherally inserted central catheters (PICC), hemodialysis access devices, implantable ports, and drug delivery systems. By addressing common issues in venous access, Access Vascular aims to improve clinical outcomes, decrease healthcare costs, and enhance patient experiences by minimizing morbidity, shortening hospital stays, and reducing pain. The company's initial focus is on launching the HydroPICC, which promises superior performance compared to existing technologies.

Kent Imaging is an innovator in multispectral oxygenation imaging, designs, manufactures, and markets imaging technology to improve plastic surgery, colorectal surgery, trauma, wound care, limb salvage, podiatry, burns and cardiac specialties. The team at Kent Imaging is committed to improving patient outcomes by delivering innovative and practical solutions for the healthcare industry. Kent Imaging holds multiple patents in medical technology and is currently commercializing the breakthrough multispectral imaging solutions that assesses tissue oxygen saturation. The company is headquartered in Calgary, Alberta, Canada, and has locations in Chicago, Los Angeles, Salt Lake City and Seattle.

Vespina Lifesciences plans to develop to proof-of-concept a potential compound with the potential to treat certain types of inflammatory diseases including pulmonary indications with poor therapeutic options as well as non-pulmonary inflammatory diseases. The compound was originally discovered and characterized at Denmark-based Neuprozyme Therapeutics ApS. There are upwards of 70,000 patients newly diagnosed with bronchiectasis in the US every year as more than half of the 16+ million patients diagnosed with COPD in the US likely also have concurrent bronchiectasis. There are no approved treatments that specifically address the underlying mechanism of disease.

ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and Crohn’s disease. The company's antibody targets a new critical target in chronic inflammation and auto-immunity which was originally discovered by Dr. Tessier in Canada.

leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs. leon-nanodrugs offers access to the next generation of nano-formulated drugs with meaningful differentiation and added patient benefits. They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles.

Emovi is dedicated to providing the highest quality, most technologically advanced products for knee joint assessment to restore patient quality of life. they are a company of knowledgeable, dedicated team members committed to innovation in healthcare.

Acer Therapeutics Inc. is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The company's clinical pipeline features several candidates, including EDSIVO, aimed at treating vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation, and ACER-001, a formulation of sodium phenylbutyrate designed for various inborn errors of metabolism, such as urea cycle disorders and maple syrup urine disease. Additionally, Acer is developing osanetant for the treatment of induced Vasomotor Symptoms and emetine hydrochloride as a potential therapeutic option for COVID-19 patients, through a collaboration with the National Center for Advancing Translational Sciences. Founded in 2013, Acer Therapeutics is headquartered in Newton, Massachusetts.

Panthera Dental Inc. is a Québec-based company that specializes in designing, developing, manufacturing, and marketing dental restoration solutions and dental sleep appliances. Founded in 2011 by brothers Gabriel and Bernard Robichaud, the company has established itself as a leader in prosthetic implant solutions. Its product offerings include Angulated Screw Channels, Metal Implant Bars, and various implant bridges such as Diamart, which enhances rigidity and supports cantilever applications. Panthera also provides innovative solutions like the Lock 'n' Release Bar for patients with dexterity challenges, D-SAD for snoring treatment, and a range of zirconia products. The company aims to enhance the quality of life for patients by delivering personalized implant systems and has expanded its presence with an office in New Jersey. With a team of over 50 employees, Panthera Dental continues to advance the field of dental restoration and sleep appliances.

Centogene AG is a leading genetic biotechnology company based in Rostock, Germany, specializing in genetic and biochemical diagnostic testing for rare hereditary disorders. The company offers a range of services to support the medical community, including genetic counseling, newborn screening, and biomarker analysis for lysosomal storage disorders. Centogene has developed a comprehensive rare disease platform that integrates epidemiologic, phenotypic, and genetic data, along with a biobank of blood samples, to aid in patient diagnosis and treatment. Additionally, the company collaborates with pharmaceutical partners to provide services such as patient recruitment, epidemiological insights, and biomarker discovery. Its diagnostic services are accessible through healthcare providers, facilitating targeted genetic sequencing for patients with various genetic disorders. With operations in multiple countries, including the United States and the United Arab Emirates, Centogene aims to improve awareness and treatment options for patients with rare diseases globally.

AL-S Pharma AG develops AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of ALS.

Ixchelsis Ltd is a clinical-stage biotechnology company based in Sandwich, United Kingdom, focusing on the development of an oxytocin receptor antagonist known as IX-01 for the treatment of premature ejaculation (PE). Founded in 2011, the company aims to establish IX-01 as a leading pharmacological option for PE. The drug has successfully completed a Phase 1 study involving healthy male volunteers and is advancing towards clinical proof of concept. Ixchelsis is supported by TVM Life Sciences Ventures VII and is led by a management team with significant expertise in pharmaceutical research and development, particularly in male sexual health. The company's initiatives are designed to provide innovative therapeutic solutions for male reproductive health issues.

AurKa Pharma is a special purpose company created to develop one compound to proof-of-concept. To date, the biopharmaceutical asset has completed GLP toxicology studies.it plans to begin clinical development in Q3-2017. Once cleared for clinical development by regulatory authorities, the it compound will be tested directly alone in solid tumors. Later on, the compound may be tested in one of a number of additional cancer indications with the goal of providing a clinical proof-of-concept of efficacy for cancer patients.

Acer Therapeutics Inc. is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The company's clinical pipeline features several candidates, including EDSIVO, aimed at treating vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation, and ACER-001, a formulation of sodium phenylbutyrate designed for various inborn errors of metabolism, such as urea cycle disorders and maple syrup urine disease. Additionally, Acer is developing osanetant for the treatment of induced Vasomotor Symptoms and emetine hydrochloride as a potential therapeutic option for COVID-19 patients, through a collaboration with the National Center for Advancing Translational Sciences. Founded in 2013, Acer Therapeutics is headquartered in Newton, Massachusetts.

leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs. leon-nanodrugs offers access to the next generation of nano-formulated drugs with meaningful differentiation and added patient benefits. They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

A special purpose company created to develop one compound to proof-of-concept.

CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Definiens specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostics, and healthcare sectors. The company offers software that delivers comprehensive readouts from whole tissue slides, cell-based assays, and full-body scans, enabling the correlation of this data with information from other sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating insights that enhance decision-making in research, diagnostics, and therapy. The company's mission is to advance research, contribute to the development of personalized medicine, and improve patient quality of life. Headquartered in Munich, Germany, Definiens also maintains offices across the United States.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Invendo Medical GmbH specializes in the development, manufacturing, and distribution of sterile, single-use, and lightweight robotically-assisted endoscopy products aimed at gastroenterology and gastrointestinal surgery. The company's flagship product, the invendoscopy E200 System, comprises a sterile colonoscope, a handheld control body, and a supply and processing unit, designed to enhance the endoscopic experience for both patients and healthcare providers. Founded in 2001 and based in Weinheim, Germany, Invendo Medical strives to be a leader in the disposable endoscopy market by focusing on innovation that improves patient compliance and increases the number of procedures performed. The company serves healthcare facilities primarily in the United States and Europe and operates as a subsidiary of Ambu A/S since 2017.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Ixchelsis Ltd is a clinical-stage biotechnology company based in Sandwich, United Kingdom, focusing on the development of an oxytocin receptor antagonist known as IX-01 for the treatment of premature ejaculation (PE). Founded in 2011, the company aims to establish IX-01 as a leading pharmacological option for PE. The drug has successfully completed a Phase 1 study involving healthy male volunteers and is advancing towards clinical proof of concept. Ixchelsis is supported by TVM Life Sciences Ventures VII and is led by a management team with significant expertise in pharmaceutical research and development, particularly in male sexual health. The company's initiatives are designed to provide innovative therapeutic solutions for male reproductive health issues.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Definiens specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostics, and healthcare sectors. The company offers software that delivers comprehensive readouts from whole tissue slides, cell-based assays, and full-body scans, enabling the correlation of this data with information from other sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating insights that enhance decision-making in research, diagnostics, and therapy. The company's mission is to advance research, contribute to the development of personalized medicine, and improve patient quality of life. Headquartered in Munich, Germany, Definiens also maintains offices across the United States.

Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.

Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Cambridge Broadband Networks Limited specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers both in the United Kingdom and internationally. The company's flagship product, VectaStar, is a multipoint microwave platform that facilitates mobile backhaul, enterprise access, and small cell network solutions. This includes offerings such as VectaStar Gigabit for macro backhaul and enterprise access, and VectaStar Metro for multipoint microwave backhaul. Additionally, the company provides a comprehensive network management system and various support services, including consultancy, training, and project management, to assist operators in designing and deploying microwave backhaul networks. Founded in 1999 and headquartered in Cambridge, the company addresses the growing demand for enhanced network capacity and efficiency in the face of increasing mobile data usage.

Anchor Therapeutics, Inc. is a biopharmaceutical company specializing in the design and development of peptide modulators for G protein-coupled receptors (GPCRs). The company focuses on creating Pepducin lipopeptide drug candidates that target the intracellular domains of GPCRs, allowing for allosteric modulation of GPCR signaling. Anchor Therapeutics aims to address various medical conditions, including cancer, inflammation, metabolic diseases, heart disease, and pain, through its innovative drug development platform. The company is engaged in pre-clinical research and offers internal programs targeting serious medical indications, such as diabetes and regenerative medicine. Originally incorporated as Ascent Therapeutics in 2006, the company rebranded to Anchor Therapeutics in 2010 and is located in Cambridge, Massachusetts.

Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.

Helomics is a personalized healthcare company based in Pittsburgh, Pennsylvania, specializing in oncology insights and contract research services. The company focuses on six primary cancers: ovarian, breast, pancreatic, colon, lung, and brain. Helomics utilizes its Precision Cellular Analytical Platform and advanced bioinformatics to deliver personalized tumor profiles, aiding physicians in making informed treatment decisions. Its portfolio includes ChemoFx, which helps in selecting effective treatments for gynecologic cancer, and various biomarker tests like BioSpeciFx and GeneFx, designed to evaluate patient tumors at a molecular level. Additionally, Helomics offers tumor profiling services, patient-derived tumor models, and multi-omics assays, enhancing the precision of cancer care. The company collaborates with pharmaceutical and diagnostic firms to improve patient outcomes through tailored diagnostic solutions and insights, ultimately supporting better clinical decision-making in oncology.

TME Pharma is a biotechnology company based in Berlin, Germany, focused on developing innovative therapeutics for cancer treatment. The company utilizes its proprietary Spiegelmer platform, which involves biostable aptamers and mirror image nucleic acids, to create a pipeline of clinical-stage product candidates. Its lead drug candidate, NOX-A12, is being investigated as a combination therapy for various cancer types, including metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. TME Pharma is also advancing NOX-E36, which has completed Phase IIa trials for diabetic nephropathy. The company has established partnerships, including a collaboration with Merck & Co. to explore the efficacy of NOX-A12 in combination with Keytruda in patients with metastatic solid tumors. Founded in 1997, TME Pharma continues to advance its mission of developing novel treatments for serious medical conditions.

DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaders such as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and Nestlé. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include Wölbern EquityPartner GmbH (Hamburg), NRW Bank (Düsseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors.

VPIsystems, formerly known as VPI Virtual Photonics, develops and markets network planning software and services for the telecommunications industry, both in the United States and internationally. The company offers products such as Photonic Design Automation, which models and optimizes photonic components, and OnePlan, an integrated system that assists communications service providers, systems integrators, and manufacturers in transitioning to IP-based networks. VPIsystems aims to enhance the efficiency of network planning and engineering processes through predictive network analytics, enabling clients to optimize network integration and improve overall network reliability. The company serves a diverse clientele, including wireline and wireless carriers, broadband providers, and equipment manufacturers. Founded in 1997, VPIsystems is headquartered in Holmdel, New Jersey, with additional offices in Europe, Asia, and Australia, and maintains strategic alliances with notable firms such as Accenture and HP.

Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.

DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaders such as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and Nestlé. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include Wölbern EquityPartner GmbH (Hamburg), NRW Bank (Düsseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors.

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Arteris IP is a leading developer of on-chip interconnect fabric technology, specializing in Network-on-Chip (NoC) interconnect intellectual property (IP) for various advanced applications, including autonomous driving, 5G, and artificial intelligence systems. Founded in 2003, Arteris pioneered the commercialization of NoC technology, establishing itself as the largest provider in this field. Its products, such as the FlexNoC Interconnect IP and Ncore Cache Coherent Interconnect IP, facilitate the development of complex systems-on-chip (SoCs) by optimizing on-chip data flow and connectivity. The company also offers innovative solutions tailored for artificial intelligence and machine learning applications, including the AI Package and CodaCache Last Level Cache. Additionally, Arteris provides Resilience Packages to ensure functional safety in multibillion-transistor chips and the PIANO Timing Closure Package to address design challenges associated with chip complexity. With a strong presence in the Americas, Asia Pacific, and Europe, Arteris derives significant revenue from the Asia Pacific region, offering comprehensive support services to enhance SoC integration and deployment.

Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.

Ubidyne, established in 2005, specializes in digital active antenna technology designed to enhance mobile communications. The company's innovative Antenna Embedded Radio technology integrates micro-radio systems within antennas, eliminating the need for coaxial feeder cables, remote electrical tilt, and additional amplifiers. This integration not only reduces energy consumption but also improves radio performance, deployment flexibility, coverage, and capacity across various mobile networks. Ubidyne's products support a wide range of standards, including GSM, UMTS, HSPA+, and LTE, and are compatible with CPRI and OBSAI optical interfaces. The technology enables advanced multi-standard wireless services, making it suitable for diverse applications from pico cells to smart macro cells and distributed in-building systems.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Cambridge Broadband Networks Limited specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers both in the United Kingdom and internationally. The company's flagship product, VectaStar, is a multipoint microwave platform that facilitates mobile backhaul, enterprise access, and small cell network solutions. This includes offerings such as VectaStar Gigabit for macro backhaul and enterprise access, and VectaStar Metro for multipoint microwave backhaul. Additionally, the company provides a comprehensive network management system and various support services, including consultancy, training, and project management, to assist operators in designing and deploying microwave backhaul networks. Founded in 1999 and headquartered in Cambridge, the company addresses the growing demand for enhanced network capacity and efficiency in the face of increasing mobile data usage.

ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute in Scandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability.

ExtendMedia specializes in software and media services that assist content providers and distributors in creating, delivering, managing, and monetizing online content across various devices. The company's flagship product, OpenCASE, serves as a robust foundation for digital media businesses, enabling efficient integration with existing systems and automating large-scale content delivery processes. With over 16 years of experience, ExtendMedia has collaborated with leading communications and media companies, embedding its extensive industry knowledge into OpenCASE. This software not only enhances operational efficiency but also supports diverse business models, making it a valuable tool for media companies and network operators managing digital video content.

Silicon Hive BV supplies semiconductor intellectual properties. It designs, builds, and licenses application-specific system solutions for use in consumer electronics and mobile terminals applications by semiconductor manufacturers and original equipment manufacturers. The company’s products enable semiconductor and consumer electronics companies to make programmable integrated circuits for imaging, video, and wireless communication applications. Silicon Hive BV’s solutions and parallel processor technologies are used in camera systems, video systems, and wireless communications. The company was founded in 2003 and is based in Eindhoven, the Netherlands with additional offices in San Jose, California; Tokyo, Japan; Seoul, South Korea; and Bangalore, India. Silicon Hive BV operates independently of Koninklijke Philips Electronics NV as of April 16, 2007.

CommProve specializes in real-time Quality of Service (QoS) monitoring for wireless networks. Founded in 1996 by experts in network operations and software engineering, the company initially focused on GSM network deployment for Tier 1 customers. This early work revealed the necessity for effective measurement, analysis, and reporting of subscriber experience related to radio link performance. Today, CommProve continues to provide network monitoring, diagnostics, and analytics solutions to enhance the quality of wireless communication services.

SpePharm is a European specialty pharmaceutical company dedicated to acquiring, registering and marketing high medical value medicines throughout Europe, essentially for the hospital market. The SpePharm management team has a wealth of global experience within the pharmaceutical industry. In particular, the team has a well-established and in-depth knowledge of the European regulatory system, the hospital market, and niche and orphan products, with novel approaches and proven successes.

Since its inception, BitWave has been dedicated to the development of a universal programmable transceiver, the Softransceiver RFIC. The technology will allow wireless carriers and cell phone manufacturers to deploy more services and devices in less time with additional functionality.

Vivendy Therapeutics Ltd. is dedicated to developing enzyme replacement therapies for Morbus Morquio, a rare lysosomal storage disease caused by a genetic deficiency. Founded in 2006 and headquartered in Basel, Switzerland, the company has created a specialized recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is engineered to enhance enzyme activity. This modification significantly improves the efficacy of the therapy for MPS IVA, aiming to provide better treatment options for patients affected by this condition.

Arteris IP is a leading developer of on-chip interconnect fabric technology, specializing in Network-on-Chip (NoC) interconnect intellectual property (IP) for various advanced applications, including autonomous driving, 5G, and artificial intelligence systems. Founded in 2003, Arteris pioneered the commercialization of NoC technology, establishing itself as the largest provider in this field. Its products, such as the FlexNoC Interconnect IP and Ncore Cache Coherent Interconnect IP, facilitate the development of complex systems-on-chip (SoCs) by optimizing on-chip data flow and connectivity. The company also offers innovative solutions tailored for artificial intelligence and machine learning applications, including the AI Package and CodaCache Last Level Cache. Additionally, Arteris provides Resilience Packages to ensure functional safety in multibillion-transistor chips and the PIANO Timing Closure Package to address design challenges associated with chip complexity. With a strong presence in the Americas, Asia Pacific, and Europe, Arteris derives significant revenue from the Asia Pacific region, offering comprehensive support services to enhance SoC integration and deployment.

Winbox Technologies is a provider of Connected-TV solutions for OEM customers and service providers. IPTV receivers, video on demand systems (VoD), harddisk videorecorders (PVR / DVR), connected TV-sets and set-top-boxes can be realized with less development investments and time by using Winbox Technologies' products. Customers can either source so called “TurnKeys” which contain a complete OEM solution including hardware, software and production services or licence specific technology modules for inhouse development.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, founded in 2006. The company focuses on discovering and developing novel small-molecule drugs primarily for autoimmune and central nervous system disorders. Its key product candidates include CTP-543, currently in Phase III trials for alopecia areata; CTP-692, in Phase II trials for schizophrenia; and AVP-786, which is undergoing Phase III trials for various neurologic and psychiatric conditions, including agitation related to Alzheimer’s disease. Concert employs a unique precision deuterium chemistry platform to modify existing drug molecules, aiming to enhance efficacy and safety while reducing research and development risks. The company also maintains strategic collaborations with several pharmaceutical partners to further its research and development efforts.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

CoreOptics specializes in providing advanced solutions for high-speed optical networking applications within the telecommunications and information technology sectors. The company is recognized for its 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, which are essential for Metro, Regional, and Long Haul optical and data networks. CoreOptics advocates for open optical communication systems that can efficiently transmit data across various rates and fiber types. Its innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is notable for enabling Tier 1 systems vendors and carriers to enhance network performance without overhauling existing fiber infrastructure. By eliminating the need for Optical Compensators and Second Stage Amplifiers, CoreOptics' products can significantly lower first-in deployment costs for customers, achieving reductions of up to 30%.

Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) area. The team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities.

RIEMSER Pharma GmbH, formerly RIEMSER Arzneimittel AG, are an international specialty pharmaceutical company based in Greifswald, and a long-standing SME culture and history. They focus primarily on the distribution and life cycle management of pharmaceuticals in therapeutic niche areas with high unmet medical needs. Their core competencies lie in the areas of oncology, anti-infectives and dermatology.

Vivendy Therapeutics Ltd. is dedicated to developing enzyme replacement therapies for Morbus Morquio, a rare lysosomal storage disease caused by a genetic deficiency. Founded in 2006 and headquartered in Basel, Switzerland, the company has created a specialized recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is engineered to enhance enzyme activity. This modification significantly improves the efficacy of the therapy for MPS IVA, aiming to provide better treatment options for patients affected by this condition.

Enigma Semiconductor develops advanced silicon solutions aimed at enhancing wired communications. The company focuses on creating innovative components and subsystems for various applications, including metropolitan and access networks, enterprise and internet infrastructure, and storage systems. Enigma offers semiconductors for switching systems, line card, and backplane systems, supporting link speeds of up to 6.25G and line card speeds of up to 1x40G. The management team comprises experienced professionals with backgrounds in prominent technology firms, ensuring a strong foundation for the company's growth and innovation in the semiconductor industry.

Ascent Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, metabolic CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets.

DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaders such as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and Nestlé. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include Wölbern EquityPartner GmbH (Hamburg), NRW Bank (Düsseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Arteris IP is a leading developer of on-chip interconnect fabric technology, specializing in Network-on-Chip (NoC) interconnect intellectual property (IP) for various advanced applications, including autonomous driving, 5G, and artificial intelligence systems. Founded in 2003, Arteris pioneered the commercialization of NoC technology, establishing itself as the largest provider in this field. Its products, such as the FlexNoC Interconnect IP and Ncore Cache Coherent Interconnect IP, facilitate the development of complex systems-on-chip (SoCs) by optimizing on-chip data flow and connectivity. The company also offers innovative solutions tailored for artificial intelligence and machine learning applications, including the AI Package and CodaCache Last Level Cache. Additionally, Arteris provides Resilience Packages to ensure functional safety in multibillion-transistor chips and the PIANO Timing Closure Package to address design challenges associated with chip complexity. With a strong presence in the Americas, Asia Pacific, and Europe, Arteris derives significant revenue from the Asia Pacific region, offering comprehensive support services to enhance SoC integration and deployment.

Netviewer GmbH specializes in web conferencing solutions, enabling users to collaboratively view and edit documents online. Founded in 2001 and headquartered in Karlsruhe, Germany, the company offers a range of products, including Netviewer Meet for internet meetings, Netviewer Support for customer assistance, and Netviewer Admin for administrative tasks. Additional offerings include Netviewer Present for online meetings, educational webinars, and conventions. These services are available as software-as-a-service, catering to various applications such as project collaborations, live demonstrations, and training sessions. Netviewer also has subsidiary operations in multiple countries, including Switzerland, France, the United Kingdom, the United States, the Netherlands, Austria, Italy, Spain, Poland, and Sweden.

TME Pharma is a biotechnology company based in Berlin, Germany, focused on developing innovative therapeutics for cancer treatment. The company utilizes its proprietary Spiegelmer platform, which involves biostable aptamers and mirror image nucleic acids, to create a pipeline of clinical-stage product candidates. Its lead drug candidate, NOX-A12, is being investigated as a combination therapy for various cancer types, including metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. TME Pharma is also advancing NOX-E36, which has completed Phase IIa trials for diabetic nephropathy. The company has established partnerships, including a collaboration with Merck & Co. to explore the efficacy of NOX-A12 in combination with Keytruda in patients with metastatic solid tumors. Founded in 1997, TME Pharma continues to advance its mission of developing novel treatments for serious medical conditions.

Silicon Hive BV supplies semiconductor intellectual properties. It designs, builds, and licenses application-specific system solutions for use in consumer electronics and mobile terminals applications by semiconductor manufacturers and original equipment manufacturers. The company’s products enable semiconductor and consumer electronics companies to make programmable integrated circuits for imaging, video, and wireless communication applications. Silicon Hive BV’s solutions and parallel processor technologies are used in camera systems, video systems, and wireless communications. The company was founded in 2003 and is based in Eindhoven, the Netherlands with additional offices in San Jose, California; Tokyo, Japan; Seoul, South Korea; and Bangalore, India. Silicon Hive BV operates independently of Koninklijke Philips Electronics NV as of April 16, 2007.

ExtendMedia specializes in software and media services that assist content providers and distributors in creating, delivering, managing, and monetizing online content across various devices. The company's flagship product, OpenCASE, serves as a robust foundation for digital media businesses, enabling efficient integration with existing systems and automating large-scale content delivery processes. With over 16 years of experience, ExtendMedia has collaborated with leading communications and media companies, embedding its extensive industry knowledge into OpenCASE. This software not only enhances operational efficiency but also supports diverse business models, making it a valuable tool for media companies and network operators managing digital video content.

Azea Networks Limited, provides world-class submarine optical networking solutions Azea Networks provides world-class submarine optical networking solutions that allow operators to exploit the full potential of their existing cable assets. Azea is uniquely focused on delivering substantial, and cost effective, capacity gains over existing undersea systems. The Azea team combines extensive optical engineering experience in characterisation, system design, modelling and product implementation to provide technologies and services that are a compelling alternative to the cost and risk of deploying new submarine cable systems. Azea’s head office is in London, with manufacturing in Scotland and a number of regional support offices.

Cambridge Broadband Networks Limited specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers both in the United Kingdom and internationally. The company's flagship product, VectaStar, is a multipoint microwave platform that facilitates mobile backhaul, enterprise access, and small cell network solutions. This includes offerings such as VectaStar Gigabit for macro backhaul and enterprise access, and VectaStar Metro for multipoint microwave backhaul. Additionally, the company provides a comprehensive network management system and various support services, including consultancy, training, and project management, to assist operators in designing and deploying microwave backhaul networks. Founded in 1999 and headquartered in Cambridge, the company addresses the growing demand for enhanced network capacity and efficiency in the face of increasing mobile data usage.

Hymite is a venture funded product company bringing to market the next generation packaging platform for use with High Power (HP) / Ultra-high Brightness (UHB) LEDs. Hymite's Engineered Silicon (Si) package platform delivers new levels of performance and value to their customers developing products for Solid State Lighting applications.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, founded in 2006. The company focuses on discovering and developing novel small-molecule drugs primarily for autoimmune and central nervous system disorders. Its key product candidates include CTP-543, currently in Phase III trials for alopecia areata; CTP-692, in Phase II trials for schizophrenia; and AVP-786, which is undergoing Phase III trials for various neurologic and psychiatric conditions, including agitation related to Alzheimer’s disease. Concert employs a unique precision deuterium chemistry platform to modify existing drug molecules, aiming to enhance efficacy and safety while reducing research and development risks. The company also maintains strategic collaborations with several pharmaceutical partners to further its research and development efforts.

Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.

RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. The company focuses on patients suffering from acute renal failure and additional indications where kidney function is compromised. It develops RBI-01, which utilizes physiologically active human renal epithelial cells and administered ex vivo, to replace and maintain severely compromised, or lost kidney functions due to illness, or trauma. The company was founded in 1995 as Nephros Therapeutics, Inc. and changed its name to RenaMed Biologics, Inc. in 2005. RenaMed Biologics, Inc. is based in Lincoln, Rhode Island.

Magen BioSciences is a Biotechnology company located in 100 Beaver Street, Suite 101, Waltham, MA, United States.

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, founded in 2006. The company focuses on discovering and developing novel small-molecule drugs primarily for autoimmune and central nervous system disorders. Its key product candidates include CTP-543, currently in Phase III trials for alopecia areata; CTP-692, in Phase II trials for schizophrenia; and AVP-786, which is undergoing Phase III trials for various neurologic and psychiatric conditions, including agitation related to Alzheimer’s disease. Concert employs a unique precision deuterium chemistry platform to modify existing drug molecules, aiming to enhance efficacy and safety while reducing research and development risks. The company also maintains strategic collaborations with several pharmaceutical partners to further its research and development efforts.

CoreOptics specializes in providing advanced solutions for high-speed optical networking applications within the telecommunications and information technology sectors. The company is recognized for its 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, which are essential for Metro, Regional, and Long Haul optical and data networks. CoreOptics advocates for open optical communication systems that can efficiently transmit data across various rates and fiber types. Its innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is notable for enabling Tier 1 systems vendors and carriers to enhance network performance without overhauling existing fiber infrastructure. By eliminating the need for Optical Compensators and Second Stage Amplifiers, CoreOptics' products can significantly lower first-in deployment costs for customers, achieving reductions of up to 30%.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

Helomics is a personalized healthcare company based in Pittsburgh, Pennsylvania, specializing in oncology insights and contract research services. The company focuses on six primary cancers: ovarian, breast, pancreatic, colon, lung, and brain. Helomics utilizes its Precision Cellular Analytical Platform and advanced bioinformatics to deliver personalized tumor profiles, aiding physicians in making informed treatment decisions. Its portfolio includes ChemoFx, which helps in selecting effective treatments for gynecologic cancer, and various biomarker tests like BioSpeciFx and GeneFx, designed to evaluate patient tumors at a molecular level. Additionally, Helomics offers tumor profiling services, patient-derived tumor models, and multi-omics assays, enhancing the precision of cancer care. The company collaborates with pharmaceutical and diagnostic firms to improve patient outcomes through tailored diagnostic solutions and insights, ultimately supporting better clinical decision-making in oncology.

Cambridge Broadband Networks Limited specializes in developing and deploying microwave access and wireless backhaul solutions for telecommunications providers both in the United Kingdom and internationally. The company's flagship product, VectaStar, is a multipoint microwave platform that facilitates mobile backhaul, enterprise access, and small cell network solutions. This includes offerings such as VectaStar Gigabit for macro backhaul and enterprise access, and VectaStar Metro for multipoint microwave backhaul. Additionally, the company provides a comprehensive network management system and various support services, including consultancy, training, and project management, to assist operators in designing and deploying microwave backhaul networks. Founded in 1999 and headquartered in Cambridge, the company addresses the growing demand for enhanced network capacity and efficiency in the face of increasing mobile data usage.

Curacyte GmbH is a biopharmaceutical company based in Munich, Germany, founded in 2001. The company specializes in developing therapeutics for acute and critical care, focusing on advanced biopharmaceutics aimed at treating conditions in hematology, antithrombosis, and oncology. By creating innovative medicines, Curacyte seeks to provide new generation treatments that address the needs of patients facing severe health challenges.

Newron Pharmaceuticals S.p.A. is a clinical stage biopharmaceutical company, established in 1999 and headquartered in Bresso, Italy, with a subsidiary in Morristown, New Jersey, USA. The company specializes in the research, development, manufacture, and distribution of therapies aimed at treating conditions affecting the central and peripheral nervous systems, as well as pain management. Its lead product, Xadago (safinamide), is approved for the treatment of Parkinson’s disease and is marketed in collaboration with various partners. Newron's product pipeline includes Sarizotan, intended for patients with Rett syndrome, Evenamide, which is being developed as a first add-on therapy for positive symptoms of schizophrenia, and Ralfinamide, targeting specific rare pain indications. The company’s innovative focus is on addressing unmet medical needs in neurology and pain management.

Impress Software Solutions, Inc. specializes in providing packaged integration applications that facilitate the seamless integration of project management and geographical information systems with SAP. Its key products include Impress for EPM, which synchronizes project-related data between SAP PM/PS and tools like Microsoft Project or Primavera, and Impress for GIS, which connects SAP assets with GIS features to maintain consistent asset information across systems. The company offers solutions for plant turnarounds, routine maintenance, information technology, capital projects, and spatial asset management, primarily serving industries such as energy and utilities, oil and gas, aerospace and defense, chemicals, and engineering and construction. Founded in 1997, Impress Software is headquartered in Waltham, Massachusetts, with additional offices in Hannover, Germany, and the Netherlands. It operates as a subsidiary of Impress Software GmbH and has established strategic partnerships with notable firms including Accenture, ESRI, Microsoft, Primavera, and SAP.

Ubidyne, established in 2005, specializes in digital active antenna technology designed to enhance mobile communications. The company's innovative Antenna Embedded Radio technology integrates micro-radio systems within antennas, eliminating the need for coaxial feeder cables, remote electrical tilt, and additional amplifiers. This integration not only reduces energy consumption but also improves radio performance, deployment flexibility, coverage, and capacity across various mobile networks. Ubidyne's products support a wide range of standards, including GSM, UMTS, HSPA+, and LTE, and are compatible with CPRI and OBSAI optical interfaces. The technology enables advanced multi-standard wireless services, making it suitable for diverse applications from pico cells to smart macro cells and distributed in-building systems.

Amnis Corporation engages in the development, manufacture, and marketing of cell analysis systems for the imaging and analysis of cells in flow. It provides ImageStream, an instrument that combines the functionalities of microscopy and flow cytometry in a single platform for various applications in drug discovery, basic biomedical research, and diagnostics. The company also offers upgrades for ImageStream system to add additional functionality, including violet and red lasers, and an extended depth of field technology (EDF) option. In addition, it provides IDEAS, a cell image analysis software that is used for the quantitative analysis of cell images, as well as for the evaluation of image-based data in various cell populations. Further, the company provides a calibration reagent for the operation of ImageStream system that allows the instrument to track flow rate and core position; and a sheath solution for the functioning of ImageStream system. Its systems are used in apoptosis, immune synapse analysis, nuclear translocation, leukocyte classification, cell cycle analysis, cell morphology analysis, intracellular molecular trafficking, surface markers co-localization, and gene expression quantitation applications. The company offers its products to academic, biotechnology, and pharmaceutical customers. Amnis Corporation was founded in 1998 and is headquartered in Seattle, Washington.

WILEX a biopharmaceutical company, develops drugs and diagnostic agents to detect cancer, treat malignant tumours, and prevent metastases. Its product line includes RENCAREX, a phase III substance for the treatment of non-metastatic renal cell cancer; REDECTANE, a phase III substance for the treatment of renal mass; and MESUPRON, a phase II substance for the treatment of pancreatic and breast cancer. The company's products also comprise the MEK inhibitor WX-554, which is under Phase I clinical trial; and the other oncology projects, including PI3K inhibitor WX-037 and three antibody programmes under preclinical development. It has a strategic alliance with UCB Pharma S.A. to develop preclinical oncology portfolio. The company was founded in 1997 and is headquartered in Munich, Germany.

Sirtris Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of proprietary, orally available small molecule drugs aimed at treating diseases related to aging. The company's research primarily focuses on metabolic disorders, including Type 2 Diabetes. By leveraging innovative approaches in drug development, Sirtris seeks to address the growing healthcare challenges associated with age-related diseases.

VPIsystems, formerly known as VPI Virtual Photonics, develops and markets network planning software and services for the telecommunications industry, both in the United States and internationally. The company offers products such as Photonic Design Automation, which models and optimizes photonic components, and OnePlan, an integrated system that assists communications service providers, systems integrators, and manufacturers in transitioning to IP-based networks. VPIsystems aims to enhance the efficiency of network planning and engineering processes through predictive network analytics, enabling clients to optimize network integration and improve overall network reliability. The company serves a diverse clientele, including wireline and wireless carriers, broadband providers, and equipment manufacturers. Founded in 1997, VPIsystems is headquartered in Holmdel, New Jersey, with additional offices in Europe, Asia, and Australia, and maintains strategic alliances with notable firms such as Accenture and HP.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.